PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine

PHASE1TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Neoplasms
Interventions
DRUG

PF-00477736

"* Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~* If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."

DRUG

gemcitabine

gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).

Trial Locations (7)

3002

Pfizer Investigational Site, East Melbourne

10022

Pfizer Investigational Site, New York

10065

Pfizer Investigational Site, New York

90095

Pfizer Investigational Site, Los Angeles

90403

Pfizer Investigational Site, Santa Monica

90404

Pfizer Investigational Site, Santa Monica

90095-6984

Pfizer Investigational Site, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00437203 - PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine | Biotech Hunter | Biotech Hunter